Posted by Michael Wonder on 19 Jul 2022
Ascentage Pharma and Innovent announce the China NMPA accepted and granted priority review designation to a new drug application for olverembatinib for the treatment of drug resistant CML
19 July 2022 - Ascentage Pharma and Innovent Biologics today announce that the Center for Drug Evaluation of China's NMPA has accepted and granted priority review designation to a new drug application that will support the full approval of olverembatinib in patients with chronic-phase chronic myeloid leukaemia who are resistant and/or intolerant of first- and second-generation tyrosine kinase inhibitors.
Following the conditional new drug application approval in November 2021, the acceptance for the latest application marks another milestone and will potentially bring olverembatinib to benefit a broader population of patients with chronic myeloid leukaemia.
